ReGenX's AAV Vector Technology gives extremely efficient and stable gene expression in neonatal and adult animals, and can be used to create disease models and to study gene function and target ...
Previous efforts to circumvent the problem of the size limitation imposed by the AAV vector have focused mainly on altering the candidate genes into ‘mini-expression cassettes’ suitable for ...
Bio-Rad delivers a comprehensive solution for AAV vector characterization, driving the development of safe and effective ... and percentage of full capsids in purified or unpurified (crude lysate) ...
Dyno’s platform integrates AI with high-throughput experimentation to accelerate the design of AAV capsids that significantly outperform existing gene delivery vectors. Just as exponential ...
The capsid license follows an agreement between Dyno and Roche originally announced in May 2020 and marks Dyno’s first adeno-associated virus (AAV ... of our sequence design capabilities ...